Heidi Ford has laced up her sneakers and set out to walk 100 miles in the area in support of the American Cancer Society.

IGHV mutational status has long been used by clinicians to predict how CLL will behave and when treatment may be needed. 2 ...

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...

In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue ...

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

Eli Lilly and Company (NYSE:LLY) said its therapy Jaypirca achieved the primary endpoint in a Phase 3 trial involving ...

Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca ...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic ...

Noah was crowned as the winner of the HGTV competition show’s inaugural season on Monday, April 6, beating the likes of fellow finalists Dean Bell, Sam McKinney, and Tammy Ly. During filming, Noah ...

To overcome the challenges of current CAR T-cell strategies and enhance their efficacy and specificity for acute myeloid leukemia, researchers at the Sino-American Cancer Foundation and collaborating ...

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the ...